Snapshot from Sep 13, 2026 at 07:00 UTC. For live data and tracking: View Live
Regulatory product recall

Vitruvias Thyroid Tablets Superpotency Recall

Analysis based on 9 articles · First reported Aug 25, 2026 · Last updated Aug 26, 2026

Sentiment
-20
Attention
2
Articles
9
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The recall may modestly affect Vitruvias Therapeutics' reputation and sales, though the limited scope (one lot) and lack of reported adverse events mitigate financial impact. The broader scrutiny on thyroid medications could influence regulatory oversight and consumer confidence in the sector.

Pharmaceuticals

Vitruvias Therapeutics voluntarily recalled one lot (504950) of Thyroid Tablets, USP 30 mg, distributed nationwide in the U.S., after testing indicated the tablets could be 'superpotent,' posing a risk of hyperthyroidism. The recall was announced by the FDA on August 24, 2026, and affects 3,655 units, of which 1,955 were sold. The company has not received reports of adverse events. Patients are advised to consult healthcare providers before discontinuing use. The recall is being conducted with FDA knowledge, and wholesalers are being notified to stop distribution and arrange destruction. The FDA also recently classified a separate recall of Levothyroxine Sodium Tablets by Intas Pharmaceuticals as Class II due to subpotency, and sent a warning letter to Intas Pharmaceuticals regarding manufacturing practices.

priv
Voluntarily recalled one lot of thyroid tablets due to superpotency, potentially affecting its reputation and sales, though no adverse events reported.
Importance 100.0 Sentiment -30.0
govactor
Published the recall notice and oversees the recall process, reinforcing its regulatory role in ensuring drug safety.
Importance 80.0 Sentiment 10.0
priv
As owner of Vitruvias, may face indirect reputational impact from the recall.
Importance 40.0 Sentiment -20.0
priv
Separately had a Class II recall for subpotent levothyroxine tablets, highlighting broader quality issues in thyroid medications.
Importance 30.0 Sentiment -15.0
govactor
Provided background information on hyperthyroidism, not directly impacted.
Importance 10.0 Sentiment 0.0
ngo
Provided statistics on thyroid disease prevalence, not directly impacted.
Importance 10.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.